Ulrich Koller

List of Publications by Year
in descending order

43	912	394390 19	501174 28
papers	citations	h-index	g-index

44	44	44	595
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	COL7A1 Editing via CRISPR/Cas9 in Recessive Dystrophic Epidermolysis Bullosa. Molecular Therapy, 2017, 25, 2573-2584.	8.2	81
2	Cut and Paste: Efficient Homology-Directed Repair of a Dominant Negative KRT14 Mutation via CRISPR/Cas9 Nickases. Molecular Therapy, 2017, 25, 2585-2598.	8.2	73
3	5â€² Trans-Splicing Repair of the PLEC1 Gene. Journal of Investigative Dermatology, 2008, 128, 568-574.	0.7	64
4	K14 mRNA reprogramming for dominant epidermolysis bullosa simplex. Human Molecular Genetics, 2010, 19, 4715-4725.	2.9	55
5	Traceless Targeting and Isolation of Gene-Edited Immortalized Keratinocytes from Epidermolysis Bullosa Simplex Patients. Molecular Therapy - Methods and Clinical Development, 2017, 6, 112-123.	4.1	40
6	QR-313, an Antisense Oligonucleotide, ShowsÂTherapeutic Efficacy for Treatment ofÂDominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study. Journal of Investigative Dermatology, 2021, 141, 883-893.e6.	0.7	36
7	A Gene Gun-mediated Nonviral RNA trans-splicing Strategy for Col7a1 Repair. Molecular Therapy - Nucleic Acids, 2016, 5, e287.	5.1	35
8	Improved Double-Nicking Strategies for COL7A1-Editing by Homologous Recombination. Molecular Therapy - Nucleic Acids, 2019, 18, 496-507.	5.1	34
9	Gene Editingâ€“Mediated Disruption of Epidermolytic Ichthyosisâ€“Associated KRT10 Alleles Restores Filament Stability in Keratinocytes. Journal of Investigative Dermatology, 2019, 139, 1699-1710.e6.	0.7	30
10	Context-Dependent Strategies for Enhanced Genome Editing of Genodermatoses. Cells, 2020, 9, 112.	4.1	29
11	A novel screening system improves genetic correction by internal exon replacement. Nucleic Acids Research, 2011, 39, e108-e108.	14.5	28
12	<scp>RNA</scp>â€based therapies for genodermatoses. Experimental Dermatology, 2017, 26, 3-10.	2.9	28
13	Gene editing for skin diseases: designer nucleases as tools for gene therapy of skin fragility disorders. Experimental Physiology, 2018, 103, 449-455.	2.0	28
14	Predictable CRISPR/Cas9-Mediated COL7A1 Reframing for Dystrophic Epidermolysis Bullosa. Journal of Investigative Dermatology, 2020, 140, 1985-1993.e5.	0.7	28
15	Spliceosome-Mediated RNA Trans-Splicing Facilitates Targeted Delivery of Suicide Genes to Cancer Cells. Molecular Cancer Therapeutics, 2011, 10, 233-241.	4.1	27
16	A Reporter-Based Screen to Identify Potent 3â€™ Trans-Splicing Molecules for Endogenous RNA Repair. Human Gene Therapy Methods, 2013, 24, 19-27.	2.1	24
17	Considerations for a Successful RNA Trans-splicing Repair of Genetic Disorders. Molecular Therapy - Nucleic Acids, 2014, 3, e157.	5.1	24
18	Advances in Gene/Cell Therapy in Epidermolysis Bullosa. Keio Journal of Medicine, 2015, 64, 21-25.	1.1	24

#	Article	IF	Citations
19	The design and optimization of RNA transâ€splicing molecules for skin cancer therapy. Molecular Oncology, 2013, 7, 1056-1068.	4.6	22
20	An RNA-targeted therapy for dystrophic epidermolysis bullosa. Nucleic Acids Research, 2017, 45, 10259-10269.	14.5	21
21	RNA Trans-Splicing for Genodermatoses. Methods in Molecular Biology, 2013, 961, 441-455.	0.9	21
22	Trans-Splicing Improvement by the Combined Application of Antisense Strategies. International Journal of Molecular Sciences, 2015, 16, 1179-1191.	4.1	16
23	RNA Trans-Splicing Modulation via Antisense Molecule Interference. International Journal of Molecular Sciences, 2018, 19, 762.	4.1	15
24	A non-viral and selection-free COL7A1 HDR approach with improved safety profile for dystrophic epidermolysis bullosa. Molecular Therapy - Nucleic Acids, 2021, 25, 237-250.	5.1	14
25	Functional therapies for cutaneous wound repair in epidermolysis bullosa. Advanced Drug Delivery Reviews, 2018, 129, 330-343.	13.7	13
26	Generation of rabbit polyclonal human and murine collagen VII monospecific antibodies: A useful tool for dystrophic epidermolysis bullosa therapy studies. Matrix Biology Plus, 2019, 4, 100017.	3.5	13
27	Personalized Development of Antisense Oligonucleotides for Exon Skipping Restores Type XVII Collagen Expression in Junctional Epidermolysis Bullosa. International Journal of Molecular Sciences, 2021, 22, 3326.	4.1	11
28	Paired nicking-mediated COL17A1 reframing for junctional epidermolysis bullosa. Molecular Therapy, 2022, 30, 2680-2692.	8.2	11
29	Advances in gene editing strategies for epidermolysis bullosa. Progress in Molecular Biology and Translational Science, 2021, 182, 81-109.	1.7	10
30	Gene Replacement Therapies for Genodermatoses: A Status Quo. Frontiers in Genetics, 2021, 12, 658295.	2.3	9
31	Cancer-type organic anion transporting polypeptide 1B3 is a target for cancer suicide gene therapy using RNA trans -splicing technology. Cancer Letters, 2018, 433, 107-116.	7.2	8
32	5â€²RNA Trans-Splicing Repair of COL7A1 Mutant Transcripts in Epidermolysis Bullosa. International Journal of Molecular Sciences, 2022, 23, 1732.	4.1	8
33	Designing Efficient Double RNA trans-Splicing Molecules for Targeted RNA Repair. International Journal of Molecular Sciences, 2016, 17, 1609.	4.1	7
34	Current developments in gene therapy for epidermolysis bullosa. Expert Opinion on Biological Therapy, 2022, 22, 1137-1150.	3.1	7
35	Selective Activation of CNS and Reference PPARGC1A Promoters Is Associated with Distinct Gene Programs Relevant for Neurodegenerative Diseases. International Journal of Molecular Sciences, 2021, 22, 3296.	4.1	5
36	Evaluating a Targeted Cancer Therapy Approach Mediated by RNA trans-Splicing In Vitro and in a Xenograft Model for Epidermolysis Bullosa-Associated Skin Cancer. International Journal of Molecular Sciences, 2022, 23, 575.	4.1	4

#	Article	IF	Citations
37	Advances on potential therapeutic options for epidermolysis bullosa. Expert Opinion on Orphan Drugs, 2018, 6, 283-293.	0.8	3
38	Therapy Development for Epidermolysis Bullosa. , 0, , .		2
39	Transcriptome-Guided Drug Repurposing for Aggressive SCCs. International Journal of Molecular Sciences, 2022, 23, 1007.	4.1	2
40	High-Throughput Screening for Highly Functional RNA-Trans-Splicing Molecules: Correction of Plectin in Epidermolysis Bullosa Simplex. , 0, , .		1
41	Molecular Research and Treatment of Skin Diseases. International Journal of Molecular Sciences, 2022, 23, 5435.	4.1	1
42	Spliceosome Mediated RNA Trans-Splicing for Targeting Kappa+ B-Cell Neoplasms. Blood, 2014, 124, 3633-3633.	1.4	0
43	Cancer-type organic anion transporting polypeptide 1B3 is a promising target for spliceosome-mediated RNA trans-splicing based suicide gene therapy. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-6-19.	0.0	0